www.standoutstocks.com: Stocks That Stand Out For Nov. 17th, 2009 Are GOVX, BIEL, BLVI, SNBP, CNOA

Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354 Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at HYPERLINK "http://www.Standoutstocks.com/" www.Standoutstocks.com

_________________________________________________

FDA Grants GeoVax Labs, Inc. Request For Pre-IND Meeting

ATLANTA, Nov 17, 2009 -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX) (the "Company"), an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that the U.S. Food and Drug Administration (FDA) has granted its request for a pre-IND meeting to discuss the proposed Investigational New Drug (IND) application for GeoVax's therapeutic vaccine as a treatment for individuals already infected with HIV. The meeting will only take place if the Company is not satisfied or requires some clarification to the FDA's answers to the questions submitted in the pre-IND package. Following the FDA response to the Pre-IND meeting questions, GeoVax will prepare and submit to the FDA an IND application for the therapeutic trial.

Robert McNally, Ph.D., president and chief executive officer, stated, "In anticipation of a pre-IND meeting in mid December, we have submitted a pre-IND information packet to the FDA. This packet includes rationale and supporting data for each question in the pre-IND package to allow a response from the FDA. The main purpose of the Pre-IND meeting is to ensure the FDA understands the purpose, approach and endpoints for the anticipated Phase 1 therapeutic trial and that we have answers to all of our questions to the FDA prior to filing the actual IND.

"While there are no guarantees of success for our therapeutic IND package, the pre-IND process helps ensure that our IND will adequately address any concerns the FDA may have about the proposed therapeutic trial," Dr. McNally added. "We understand the extreme need for this vaccine and we understand the process necessary to navigate forward." A new IND with the FDA is required since this will be the first time the GeoVax vaccine will be used for a therapeutic application. The Phase 1 therapeutic protocol stresses safety parameters to minimize any risk to the volunteers. The protocol, conceived with collaboration from ARCA (AIDS Research Consortium of Atlanta), has specific objectives to optimize safety while evaluating the ability for the vaccine to elicit protective immune responses in vaccinated participants. The proposed trial is based on the achievement of excellent post-vaccine viral control in animal trials conducted in recently infected non-human primates at the Yerkes National Primate Research Center, affiliated with Emory University. The proposed human trial follows the precedents set in the preclinical animal trials and is a critical step towards developing a therapeutic vaccine for HIV-1 infected humans.

The IND process is expected to take a number of months to complete. Based on the Company's current progress, commencement of the trial is targeted for early 2010.

HIV affects the entire globe and comes in a variety of subtypes. Clade B is the predominant subtype in North America, where there are roughly 60,000 new infections each year. Globally, there are about 2.5 million AIDS infections per year, most primarily involving subtypes AG, B, and C. In 2007, UNAIDS reported 1.3 million people living with AIDS in North America and 33.2 million people living with AIDS worldwide.

About GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person become infected. GeoVax AIDS vaccines also may be effective as a therapeutic treatment (for people already infected with the HIV-1 virus).

GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet Robinson, Senior V.P. of Research and Development, through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.

GeoVax's AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $17 million IPCAVD grant awarded in late 2007.

Safe Harbor Statement All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.

BioElectronics Technology More Effective Than Extra Strength Tylenol(R) in Reducing Muscle Soreness in Clinical Study

ActiPatch Proved 50 Percent More Effective Than Acetaminophen

FREDERICK, MD, Nov 16, 2009 -- BioElectronics Corp. (PINKSHEETS: BIEL | Quote | Chart | News | PowerRating) today announced that its disposable drug-free anti-inflammatory devices proved to be significantly more effective than acetaminophen in a clinical study of Delayed Onset Muscle Soreness (DOMS).

The study tested the effectiveness of ActiPatch(R) Therapy versus acetaminophen in reducing the pain of Delayed Onset Muscle Soreness, a condition associated with increased physical exertion.

"We now have an additional Institutional Review Board (IRB) supervised and National Institutes of Health (NIH) registered clinical study that demonstrates what our customers have been saying for years," said Andrew Whelan, CEO, BioElectronics Corp. "Our products give fast, localized relief from pain and swelling without the danger of drug side effects. We plan to use this additional study to further support our pending 510(K) applications on file at FDA as well as possibly using them in additional applications." "In the study more than 100 healthy male and female college athletes and trainers were given a vigorous resistance exercise regimen to induce DOMS. They were then randomly divided into three groups; a group that used ActiPatch for two days, a control group that received no treatment, and a third group that was to be treated with acetaminophen," commented Sheena Kong, M.D. the principal investigator. "All participants returned approximately 48 hours after the exercise regime. Upon return those in the ActiPatch and control groups immediately rated their levels of muscle pain and soreness using the Visual Analogue Scale. Participants in the acetaminophen group were given one gram of acetaminophen in the form of Extra Strength Tylenol(R) and then 90 minutes later rated their levels of muscle pain and soreness using the same scale." Dr. Kong continued, "The study was conclusive showing that the ActiPatch treated volunteers had significantly less pain than those in either the acetaminophen or control groups. Also of note was the fact that some of the participants assigned to the acetaminophen group were eliminated from the results because they expressed reservations about consuming the drug." The report notes that there was a highly significant difference between the control group and the group using the ActiPatch, with the control group indicating an average VAS pain level of 3.179 compared to 1.500 for the ActiPatch group where lower numbers indicate lower pain levels. This difference between the two groups was found to be significant at the .001 level. The difference between the acetaminophen group and the ActiPatch group was also highly significant with the acetaminophen group indicating an average pain level of 2.507, i.e., over one point higher than the ActiPatch group. This difference was found to be significant at the .05 level.

ActiPatch technology truncates the human body's natural inflammatory response by breaking the cycle of chronic inflammation. ActiPatch does this by delivering sensation-free pulsed electromagnetic energy and RF waves directly to the affected area and driving out the edematous fluid along with byproducts of the damaged tissue. The effect is well documented and results in a significant overall improvement in the restorative and recovery process following a soft tissue injury. This speedier healing results in a significant reduction in the pain associated with the injury. ActiPatch has been used by thousands of people throughout the world and maintains a 100% safety profile.

The study is Institutional Review Board (IRB) supervised and has been registered with the National Institutes of Health. The principal investigator, Sheena Kong, M.D. holds no financial position in any form in the study's sponsor, BioElectronics Corp., and has not and will not receive financial compensation of any kind for the administration or completion of the study. The acetaminophen used in the study was Extra Strength Tylenol(R) in 1 gram doses.

A complete copy of the study results and protocol is available on the BioElectronics Corp. web site: http://www.bioelectronicscorp.com.

About BioElectronics Corporation BioElectronics Corporation is the maker of ActiPatch(R) Therapy, RecoveryRx(TM) Devices, HealFast(R) Therapy www.healfasttherapy.com and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.

Black Art Beer and Karu&Y Light-Up the Miami Nightlife

Premier German Importer to Market at Busy Miami Night Venue

FORT LAUDERDALE, FL, Nov 16, 2009 -- Black Art Beverage Inc. (PINKSHEETS: BLVI | Quote | Chart | News | PowerRating) announced today that it was going to promote its Dark and Golden beer varieties at the Karu&Y Miami nightclub complex from Thanksgiving straight through the Super Bowl in January.

The Karu&Y is a multi-faceted club featuring a restaurant, a Buddha garden, and a 5000 sq ft dance club with seating for up to 1,200 patrons. Past celebrity guests have included Nicky and Paris Hilton, Hugh Hefner and the Playboy girls. More information on the Karu&Y with multimedia is available on their website http://www.karu-y.com/main.html.

"What a great opportunity for Black Art to gain exposure within the Miami and celebrity scene by showcasing at Karu&Y during the holidays. We are really looking forward to this marketing event to ignite distribution on South Beach and the entire Miami region," said Mike Coffman, COO of Black Art Beverage Inc.

For information on other Black Art Beer events please see our website http://www.blackartbeer.com or look for us on Facebook as Black Art Beer and become a friend of the brewery.

About Black Art Beer Black Art Beer is produced in Germany and exported to the United States exclusively through Black Art Importers. Black Art's current products include the flagship Black Art beer, a dark premium pilsner, and Black Art Gold, a smooth and light pilsner. Other styles and draft keg beer is forthcoming. For more information, please visit: www.blackartbeer.com.

About Black Art Beer Importers, Inc.

Black Art Importers is a Florida corporation engaged in the business of distributing the Black Art brand. Black Art Beer Importers, Inc. is a wholly owned operating company of Black Art Beverage, Inc.

About Braustolz Brauerie AG.

Black Art pilsner beers are brewed and bottled by Braustolz GmbH in Germany. Braustolz has been in operation since 1868, brewing beer according to the German Purity Laws of 1516, which results in superior quality. Braustolz is a wholly owned subsidiary of a Brewery Group headed by Kulmbacher Brewery all based in Germany.

Forward-Looking Statements Statements made in this press release that are not historical facts constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21 of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such statements rely on a number of assumptions concerning future events, many of which are outside of the Company's control, and involve risks and uncertainties that could cause actual results to differ materially from opinions and expectations. All information in this release is as of the date hereof. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

For further information regarding Black Art's business, please refer to the "Information and Disclosure Statement" available on www.pinksheets.com. Additional information about Black Art is available on the World Wide Web at www.blackartbeer.com.

Sinobiopharma has Production Rights to 23 Drugs Listed in China's National Essential Drugs List

--All Drugs on List to be Covered by Basic Government Insurance That Will Cover 90 Percent of China's Population NANTONG, China, Nov 16, 2009 -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC Bulletin Board: SNBP | Quote | Chart | News | PowerRating) is pleased to announce that 23 generic drugs for which the Company has production rights are listed in China's National Essential Drugs List, which covers pharmaceuticals used to treat up to 80 percent of the most common diseases in China.

According to the Chinese government's healthcare reform plan, 90 percent of China's citizens will be covered by a universal healthcare system by the year 2010. Under the plan, drugs on the National Essential Drugs List (the "List") will be purchased by various levels of government first, then distributed to medical facilities. All drugs on the List will be covered by the basic insurance plan supported by the government. The plan also calls for medical facilities to be upgraded, which includes the construction of 30,000 new hospitals, clinics and care centers across China.

"While Sinobiopharma is primarily focused on the development, production and distribution of "me-too/me-better" branded new or generic drugs with high margins, the inclusion of 23 generic drugs for which the Company owns production rights on the National Essential Drugs List, will enable us to increase both sales and margins," said Dr. Lequn Lee Huang, Sinobiopharma President and CEO. "We expect that this new advantage in the marketplace will also enable the Company to enhance our ability to improve return on investment for shareholders in 2010." About Sinobiopharma Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.

China Organic Agriculture, Inc. Third Quarter 2009 Financials

--Company Reports $40 Million Revenue, $4.5 Million Net Income and EPS of $0.06 for Q3 2009

SHENZHEN, China, Nov 17, 2009 -- China Organic Agriculture, Inc. (OTC Bulletin Board: CNOA) ("China Organic Agriculture" or the "Company"), a global diversified food products company engaged in the trading and distribution of agricultural products headquartered in the Liaoning province in China, today announced its financial results for the three and nine months ended September 30, 2009.

Financial Highlights 1) Sales revenue and gross profit for the third quarter, inclusive of the portions attributable to the minority interest in its subsidiary, Dalian Huiming, were $39.7 million and $11.1 million. Although sales decreased 15% as compared to the prior year, gross profit was approximately equal to that of last year's comparable period, reflecting the Company's focus on higher margin trading opportunities.

2) Sales revenue and gross profit for the nine months, inclusive of the portions attributable to the minority interest in its subsidiary, Dalian Huiming, were $106.4 million and $26.4 million, a year-over-year increase of 97.4% and 103.8% respectively.

3) Selling, general and administrative expenses declined by 9.5% for the first nine months as compared to the same period a year ago in spite of the near doubling of revenues.

4) Earnings per share from continuing operations attributable to the Company for the quarter was $0.06, a substantial decrease from the $0.15 from continuing operations recorded in the comparable period last year.

Sales for the nine months ending September 30, 2009 totaled $106.4 million compared to $53.9 million for the same period last year. This increase of $52.5 million is attributable to the Company's acquisition of 60% of the equity of Dalian Huiming Industry Ltd. ("Dalian Huiming") in October 2008, which accounted for the substantial revenue growth for the nine-month period.

Although the sales during the three months ended September 30th were lower than same period last year, because the Company achieved improved gross and operating margins its gross profit for the third quarter of 2009 was comparable to the third quarter of 2008. The increase in gross profit for the nine-month period resulted from the increased revenue was attributable to Dalian Huiming.

Net income attributable to CNOA shareholders was $4.5 million for the third quarter of 2009, compared to net income of $8.5 million for the same period last year, excluding discontinued operations in 2008. Net income attributable to CNOA shareholders was $10.9 million for the nine months ended September 30, 2009, compared to net income of $8.5 million for the same period in 2008, again excluding discontinued operations. These results reflect the Company's ownership of 60% of Dalian Huiming. Because the Company owns only 60% of Dalian Huiming, 40% of Dalian Huiming's net income is recorded as income attributed to non-controlling interest.

The basic and diluted earnings per share for the third quarter attributable to CNOA's shareholders were $0.06, compared to last year's third quarter results of $0.15 per share, and the basic and diluted earnings per share for the nine months ended on September 30, 2009 attributable to CNOA's shareholders were $0.15 as compared to $0.16 per share in the comparable prior year period. The 2008 quarter and nine months results exclude $0.02 and $0.03 per share, respectively, from discontinued operations. A former operating subsidiary of the Company, ErMaPao, was sold effective September 30, 2008 and its results are now classified as discontinued operations in the attached schedules.

Financial Conditions On September 30, 2009, the Company's cash and cash equivalents totaled $17.3 million compared to $1.6 million as of September 30, 2008. As of September 30, 2009, current assets totaled $90 million and current liabilities were $30 million.

During the nine months ended September 30, 2009, the Company used 5.0 million in its operating activities, reflecting the increase in the Company's accounts receivable due to the increased sales for the nine-month period. The Company also recorded $5.2 million of investments and $9.8 million of cash inflows from financing activities during this period.

Business Developments On February 29, 2008, the Company acquired the California based Bellisimo Vineyard, for $14.8 million. This vineyard produces Chardonnay, Merlot and Cabernet Sauvignon wine grapes. On September 30, 2008, the Company sold its subsidiary, ErMaPao for a non-interest bearing note receivable of $8.7 million which has been paid in full.

In October 2008, the Company acquired 60% of the outstanding shares of Dalian Huiming for $10.6 million, Dalian Huiming is a top-tier agricultural trading company focused on soybeans, corn, and cereal crops, all major agricultural products in China.

About China Organic Agriculture China Organic Agriculture is based in China and is primarily engaged in the acquisition, trading and distribution of agricultural products. For more information, please visit: http://www.chinaorganicagriculture.com .

FORWARD-LOOKING STATEMENTS: This document includes forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning future acquisitions, estimates of, and increases in, production, cash flows and values, statements relating to the continued advancement of China Organic Agriculture's products and other statements which are not historical facts. When used in this document, words such as "could," "plan," "estimate," "expect," "intend," "may," and similar expressions denote forward-looking statements. Although China Organic Agriculture Inc. believes that its expectations reflected in these forward-looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Important factors that could cause actual results to differ from these forward-looking statements include, but are not limited to, those set forth in our reports filed with the Securities and Exchange Commission, together with the risks discussed in our press releases and other communications to shareholders issued by us from time to time, such as our ability to raise capital as and when required, the availability of raw products and other supplies, competition, the costs of goods, government regulations, and political and economic factors in the People's Republic of China in which our subsidiaries operate.

About Standoutstocks.com www.Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.

www.Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at http://www.Standoutstocks.com and select the "join now" button.

Join us at http://www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.

Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.

Visit us for a full Disclaimer at: http://www.standoutstocks.com/disclaimer.aspx

CONTACT: Jason A. Hilton, Standout Stocks
Tel: +1 585 729 8809
e-mail: Jason@Newmediaadvisorsllc.com
e-mail: info@standoutstocks.com
WWW: http://www.standoutstocks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on (BIEL) BIEL. (BIEL) has Short Term PowerRatings at TradingMarkets. Details on (BIEL) Short Term PowerRatings is available at This Link.

For full details on (SNBP) SNBP. (SNBP) has Short Term PowerRatings at TradingMarkets. Details on (SNBP) Short Term PowerRatings is available at This Link.

For full details on (CNOAE) CNOAE. (CNOAE) has Short Term PowerRatings at TradingMarkets. Details on (CNOAE) Short Term PowerRatings is available at This Link.

For full details on (BLVI) BLVI. (BLVI) has Short Term PowerRatings at TradingMarkets. Details on (BLVI) Short Term PowerRatings is available at This Link.